Company Filing History:
Years Active: 1993-1994
Title: Michael D Bond: Innovator in Angiogenic Protein Research
Introduction
Michael D Bond is a notable inventor based in Brighton, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of angiogenic proteins. With a total of 2 patents, his work focuses on enhancing the therapeutic potential of these proteins.
Latest Patents
Michael D Bond's latest patents include innovative research on covalent angiogenin/RNase hybrids. This research discloses regional mutagenesis of a gene for angiogenin to produce DNA sequences encoding mutant proteins that exhibit increased angiogenic activity. The expression vectors containing these sequences are introduced into host cells, directing the production of mutant angiogenic proteins with markedly enhanced activity. Notably, the replacement of amino acids in a specific region of angiogenin yields a mutant hybrid protein with a ten-fold increase in angiogenic potency, as demonstrated in the chorioallantoic membrane assay. These mutant proteins are valuable therapeutic compositions for promoting the development of a hemovascular network in mammals and for facilitating wound healing, particularly in cases of torn or traumatized fibrocartilage material.
Career Highlights
Michael D Bond is affiliated with Harvard College, where he continues to advance his research in the field of angiogenic proteins. His work has garnered attention for its potential applications in medical therapies.
Collaborations
Michael collaborates with Bert L Vallee, further enhancing the impact of his research through shared expertise and knowledge.
Conclusion
Michael D Bond's innovative work in the field of angiogenic proteins exemplifies the potential of biotechnology to address critical medical challenges. His contributions are paving the way for new therapeutic approaches in wound healing and vascular development.